<SEC-DOCUMENT>0001104659-20-072491.txt : 20200611
<SEC-HEADER>0001104659-20-072491.hdr.sgml : 20200611
<ACCEPTANCE-DATETIME>20200611172316
ACCESSION NUMBER:		0001104659-20-072491
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20200611
DATE AS OF CHANGE:		20200611
EFFECTIVENESS DATE:		20200611

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LEAP THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001509745
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				274412575
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37990
		FILM NUMBER:		20958027

	BUSINESS ADDRESS:	
		STREET 1:		47 THORNDIKE STREET
		STREET 2:		SUITE B1-1
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		617 252 4343

	MAIL ADDRESS:	
		STREET 1:		47 THORNDIKE STREET
		STREET 2:		SUITE B1-1
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Dekkun Corp
		DATE OF NAME CHANGE:	20110107
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>tm2022378d1_defa14a.htm
<DESCRIPTION>DEFA14A
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 13.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE 14A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Proxy Statement Pursuant to Section&nbsp;14(a)&nbsp;of<BR>
the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3"><FONT STYLE="font-size: 10pt">Filed by the Registrant <FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">
    Filed by a Party other than the Registrant <FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">
    Check the appropriate box:</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 17px"><FONT STYLE="font-size: 10pt">
    <FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD STYLE="width: 12px"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">
    Preliminary Proxy Statement</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">
    <FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">
    <B>Confidential, for Use of the Commission Only (as permitted by Rule&nbsp;14a-6(e)(2))</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">
    <FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">
    Definitive Proxy Statement</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">
    <FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">
    Definitive Additional Materials</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">
    Soliciting Material under &sect;240.14a-12</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.75in"><B>LEAP THERAPEUTICS,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
<TD COLSPAN="5" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="5"><FONT STYLE="color: Black"></FONT>(Name of Registrant as Specified In Its Charter)</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="5"><B>NOT APPLICABLE</B></TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="5" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 7pt"></FONT><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="5">(Name of Person(s)&nbsp;Filing Proxy Statement, if other than the Registrant)</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="5">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="5" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt"></FONT>Payment of Filing Fee (Check the appropriate box):</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="5" STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt"></FONT><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></TD>
<TD>&nbsp;</TD>
<TD COLSPAN="3" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt"></FONT>No fee required.</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD COLSPAN="3" STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt"></FONT><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
<TD>&nbsp;</TD>
<TD COLSPAN="3" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt"></FONT>Fee computed on table below per Exchange Act Rules&nbsp;14a-6(i)(1)&nbsp;and 0-11.</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 17px">&nbsp;</TD>
<TD STYLE="width: 12px">&nbsp;</TD>
<TD STYLE="font-size: 10pt; width: 20px">(1)</TD>
<TD STYLE="width: 12px">&nbsp;</TD>
<TD STYLE="border-bottom: black 1pt solid; padding-bottom: 0.5pt; font-size: 10pt">Title of each class of securities to which transaction applies:</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt">(2)</TD>
<TD>&nbsp;</TD>
<TD STYLE="border-bottom: black 1pt solid; padding-bottom: 0.5pt; font-size: 10pt">Aggregate number of securities to which transaction applies:</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt">(3)</TD>
<TD>&nbsp;</TD>
<TD STYLE="border-bottom: black 1pt solid; padding-bottom: 0.5pt; font-size: 10pt">Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule&nbsp;0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt">(4)</TD>
<TD>&nbsp;</TD>
<TD STYLE="border-bottom: black 1pt solid; padding-bottom: 0.5pt; font-size: 10pt">Proposed maximum aggregate value of transaction:</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt">(5)</TD>
<TD>&nbsp;</TD>
<TD STYLE="border-bottom: black 1pt solid; padding-bottom: 0.5pt; font-size: 10pt">Total fee paid:</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt"></FONT><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
<TD>&nbsp;</TD>
<TD COLSPAN="3" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt"></FONT>Fee paid previously with preliminary materials.</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD COLSPAN="3" STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt"></FONT><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
<TD>&nbsp;</TD>
<TD COLSPAN="3" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt"></FONT>Check box if any part of the fee is offset as provided by Exchange Act Rule&nbsp;0-11(a)(2)&nbsp;and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form&nbsp;or Schedule and the date of its filing.</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD COLSPAN="3" STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt"></FONT>(1)</TD>
<TD>&nbsp;</TD>
<TD STYLE="border-bottom: black 1pt solid; padding-bottom: 0.5pt; font-size: 10pt"><FONT STYLE="font-size: 10pt"></FONT>Amount Previously Paid:</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt">(2)</TD>
<TD>&nbsp;</TD>
<TD STYLE="border-bottom: black 1pt solid; padding-bottom: 0.5pt; font-size: 10pt">Form, Schedule or Registration Statement No.:</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt">(3)</TD>
<TD>&nbsp;</TD>
<TD STYLE="border-bottom: black 1pt solid; padding-bottom: 0.5pt; font-size: 10pt">Filing Party:</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt">(4)</TD>
<TD>&nbsp;</TD>
<TD STYLE="border-bottom: black 1pt solid; padding-bottom: 0.5pt; font-size: 10pt">Date Filed:</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2022378d1_defa14aimg01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>LEAP THERAPEUTICS,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SUPPLEMENT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICE OF ANNUAL MEETING OF STOCKHOLDERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AND PROXY STATEMENT, DATED APRIL 28,
2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FOR THE VIRTUAL ANNUAL MEETING OF STOCKHOLDERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TO BE HELD ON JUNE 16, 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>47 Thorndike Street</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Suite&nbsp;B1-1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Cambridge, MA 02141</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This supplement (this &ldquo;Supplement&rdquo;)
provides updated information with respect to the 2020 Annual Meeting of Stockholders (the &ldquo;Annual Meeting&rdquo;) of Leap
Therapeutics,&nbsp;Inc. (the &ldquo;Company&rdquo;) to be held on June&nbsp;16, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On
April&nbsp;28, 2020, the Company commenced delivering to its stockholders a Notice of Annual Meeting of Stockholders and Definitive
Proxy Statement (the &ldquo;Notice and Proxy Statement&rdquo;) for the Annual Meeting. This Supplement, including the press release
dated June&nbsp;11, 2020, included below, which describes a change in the location of the Annual Meeting from an in-person to a
virtual-only meeting, as well as a change in the time of the Annual Meeting, should be read in conjunction with the Notice and
Proxy Statement. Except as specifically revised by the information contained herein, this Supplement does not revise or update
any of the information set forth in the Notice and Proxy Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICE OF CHANGE OF LOCATION AND TIME</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OF ANNUAL MEETING OF STOCKHOLDERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TO BE HELD ON JUNE 16, 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm2022378d1_defa14aimg02.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Leap Therapeutics Announces Changes to
Virtual Format and Time for 2020 Annual Meeting of Stockholders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Cambridge, MA &ndash; June&nbsp;11, 2020</B>&nbsp;&ndash;
Leap Therapeutics,&nbsp;Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics,
today announced that, due to public health and safety concerns related to the outbreak of the novel coronavirus (&ldquo;COVID-19&rdquo;),
and to support the health and well-being of its stockholders, employees and others, the Company is changing its 2020 Annual Meeting
of Stockholders (the &ldquo;Annual Meeting&rdquo;) to a virtual-only format. The virtual Annual Meeting is expected to provide
stockholders with the same rights and opportunities to participate as they would have had at an in-person meeting. Stockholders
can submit questions related to the matters to be voted on at the virtual Annual Meeting by using the instructions on the virtual
meeting website listed below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In order to accommodate a virtual-only meeting format, the Annual
Meeting will now be held at 4:00 p.m., eastern time, on Tuesday, June&nbsp;16, 2020. Online access to the Annual Meeting will begin
at 3:45 p.m., eastern time. Stockholders will not be able to attend the Annual Meeting in person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Attending the Virtual Meeting as a Stockholder of Record</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company&rsquo;s stockholders of record as of April&nbsp;24,
2020 (the &ldquo;Record Date&rdquo;) can attend the Annual Meeting by accessing <I>https;//www.cstproxy.com/leaptx/2020</I> and
entering the control number on the proxy card previously received. Instructions on how to access the Annual Meeting and participate
via the Internet, including how to demonstrate proof of stock ownership, and voting instructions, can be found at <I>https;//www.cstproxy.com/leaptx/2020</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Attending the Virtual Meeting as a Beneficial Owner</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Beneficial stockholders as of the Record Date (i.e. shares held
in &ldquo;street name&rdquo; through an intermediary, such as a bank or broker) who want to be able to attend the Annual Meeting
can attend using the control number found on the notice and instructions received from their broker or other nominee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Attending the Virtual Meeting as a Guest</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Guests may participate in a listen-only mode. No control number
is required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Stockholders who do not have their control number will be able
to access the virtual Annual Meeting as guests but will not be able to vote their shares or submit questions during the Annual
Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Voting Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Stockholders of record and beneficial
owners will be able to vote their shares electronically during the virtual Annual Meeting by using the control number. Instructions
on how to vote while participating in the Annual Meeting live via the Internet are posted at <I>https;//www.cstproxy.com/leaptx/2020</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Whether or not stockholders plan to virtually
attend the Annual Meeting, the Company urges them to vote by one of the methods described in the proxy materials for the Annual
Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The proxy materials that were distributed along with the
definitive proxy statement will not be updated to reflect the virtual-only format of the Annual Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>List of Stockholders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A list of stockholders entitled to vote
at the Annual Meeting and instructions for accessing the stockholder list will also be available during the Annual Meeting at
<I>https;//www.cstproxy.com/leaptx/2020</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Leap Therapeutics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Leap Therapeutics (Nasdaq:LPTX) is focused on developing targeted
and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting
the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary,
gynecologic, and prostate cancers. Leap has formed a partnership with BeiGene,&nbsp;Ltd. for the rights to develop DKN-01 in Asia
(excluding Japan), Australia, and New Zealand. For more information about Leap Therapeutics, visit&nbsp;<U>http://www.leaptx.com</U>&nbsp;or
view our public filings with the SEC that are available via EDGAR at&nbsp;<U>http://www.sec.gov</U>&nbsp;or via&nbsp;<U>https://investors.leaptx.com/</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Douglas E. Onsi</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">President&nbsp;&amp; Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Leap Therapeutics,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">617-714-0360</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>donsi@leaptx.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Heather Savelle</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Investor Relations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Argot Partners</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">212-600-1902</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>heather@argotpartners.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">###</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>tm2022378d1_defa14aimg01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2022378d1_defa14aimg01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  W +4# 2(  A$! Q$!_\0
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M[;(.57N=0L:+&(U50@& H'&*BBLK6%]\5O&C8QE5 -%%;C)41(T"(H51T &
M*00QJA01J$.<KC@YHHI@0Q6%I#)YD=M$K]B%Y%3K&B%BJA2QRV!U-%% $,UC
M:W#[YK>-V]2O-5[VS4P0100H$$ZLR@ #'>BBDP+$5C:02>9%;QH_]X+S4DT$
M5PFR:-)%]&&:**8#8+6"V!$$*1YZ[1C-,?3[.1R[VT3,>22@YHHH E:WA>'R
M6B0Q_P!PKQ^5,CL[:+'EP1K@[AA0,'UHHH 6:TM[@@S01R$="R@U&^G63JJM
;:Q$+P/E'%%%%@)XHHX4"1(J*.RC HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm2022378d1_defa14aimg02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2022378d1_defa14aimg02.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  W +4# 2(  A$! Q$!_\0
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M[;(.57N=0L:+&(U50@& H'&*BBLK6%]\5O&C8QE5 -%%;C)41(T"(H51T &
M*00QJA01J$.<KC@YHHI@0Q6%I#)YD=M$K]B%Y%3K&B%BJA2QRV!U-%% $,UC
M:W#[YK>-V]2O-5[VS4P0100H$$ZLR@ #'>BBDP+$5C:02>9%;QH_]X+S4DT$
M5PFR:-)%]&&:**8#8+6"V!$$*1YZ[1C-,?3[.1R[VT3,>22@YHHH E:WA>'R
M6B0Q_P!PKQ^5,CL[:+'EP1K@[AA0,'UHHH 6:TM[@@S01R$="R@U&^G63JJM
;:Q$+P/E'%%%%@)XHHX4"1(J*.RC HHHH __9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
